313 related articles for article (PubMed ID: 16682304)
1. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin.
Rodenburg J; Vissers MN; Wiegman A; Miller ER; Ridker PM; Witztum JL; Kastelein JJ; Tsimikas S
J Am Coll Cardiol; 2006 May; 47(9):1803-10. PubMed ID: 16682304
[TBL] [Abstract][Full Text] [Related]
2. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.
Tsimikas S; Witztum JL; Miller ER; Sasiela WJ; Szarek M; Olsson AG; Schwartz GG;
Circulation; 2004 Sep; 110(11):1406-12. PubMed ID: 15353498
[TBL] [Abstract][Full Text] [Related]
3. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
[TBL] [Abstract][Full Text] [Related]
4. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.
Tsimikas S; Lau HK; Han KR; Shortal B; Miller ER; Segev A; Curtiss LK; Witztum JL; Strauss BH
Circulation; 2004 Jun; 109(25):3164-70. PubMed ID: 15184281
[TBL] [Abstract][Full Text] [Related]
5. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans.
Ky B; Burke A; Tsimikas S; Wolfe ML; Tadesse MG; Szapary PO; Witztum JL; FitzGerald GA; Rader DJ
J Am Coll Cardiol; 2008 Apr; 51(17):1653-62. PubMed ID: 18436117
[TBL] [Abstract][Full Text] [Related]
6. Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: acute effects of hemodialysis.
Bossola M; Tazza L; Merki E; Giungi S; Luciani G; Miller ER; Lin EB; Tortorelli A; Tsimikas S
Blood Purif; 2007; 25(5-6):457-65. PubMed ID: 18075247
[TBL] [Abstract][Full Text] [Related]
7. Atherogenic lipoprotein particle size and concentrations and the effect of pravastatin in children with familial hypercholesterolemia.
van der Graaf A; Rodenburg J; Vissers MN; Hutten BA; Wiegman A; Trip MD; Stroes ES; Wijburg FA; Otvos JD; Kastelein JJ
J Pediatr; 2008 Jun; 152(6):873-8. PubMed ID: 18492534
[TBL] [Abstract][Full Text] [Related]
8. OxPL/apoB, lipoprotein(a) and OxLDL biomarkers and cardiovascular disease in chronic hemodialysis patients.
Bossola M; Tazza L; Luciani G; Tortorelli A; Tsimikas S
J Nephrol; 2011; 24(5):581-8. PubMed ID: 21404224
[TBL] [Abstract][Full Text] [Related]
9. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study.
Choi SH; Chae A; Miller E; Messig M; Ntanios F; DeMaria AN; Nissen SE; Witztum JL; Tsimikas S
J Am Coll Cardiol; 2008 Jul; 52(1):24-32. PubMed ID: 18582631
[TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.
Merki E; Graham MJ; Mullick AE; Miller ER; Crooke RM; Pitas RE; Witztum JL; Tsimikas S
Circulation; 2008 Aug; 118(7):743-53. PubMed ID: 18663084
[TBL] [Abstract][Full Text] [Related]
11. Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trial.
Koeijvoets KC; Rodenburg J; Hutten BA; Wiegman A; Kastelein JJ; Sijbrands EJ
Circulation; 2005 Nov; 112(20):3168-73. PubMed ID: 16286607
[TBL] [Abstract][Full Text] [Related]
12. Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study.
Rao F; Schork AJ; Maihofer AX; Nievergelt CM; Marcovina SM; Miller ER; Witztum JL; O'Connor DT; Tsimikas S
Arterioscler Thromb Vasc Biol; 2015 Jul; 35(7):1704-11. PubMed ID: 25953646
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein-associated phospholipase A2 mass and activity in children with heterozygous familial hypercholesterolemia and unaffected siblings: effect of pravastatin.
Ryu SK; Hutten BA; Vissers MN; Wiegman A; Kastelein JJ; Tsimikas S
J Clin Lipidol; 2011; 5(1):50-6. PubMed ID: 21262507
[TBL] [Abstract][Full Text] [Related]
14. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.
Franceschini G; Sirtori M; Vaccarino V; Gianfranceschi G; Chiesa G; Sirtori CR
J Lab Clin Med; 1989 Sep; 114(3):250-9. PubMed ID: 2504855
[TBL] [Abstract][Full Text] [Related]
15. [Pravastatin increases the activity pf the LDL receptors in lymphocytes of individuals with heterozygous familial hypercholesterolemia].
Alvarez-Sala LA; Mata P; Blázquez E; Garrido JA; Ordovás JM; Rubio MJ; de Oya M
Rev Clin Esp; 1997 May; 197(5):317-22. PubMed ID: 9280964
[TBL] [Abstract][Full Text] [Related]
16. Oxidized low-density lipoprotein autoantibodies, chronic infections, and carotid atherosclerosis in a population-based study.
Mayr M; Kiechl S; Tsimikas S; Miller E; Sheldon J; Willeit J; Witztum JL; Xu Q
J Am Coll Cardiol; 2006 Jun; 47(12):2436-43. PubMed ID: 16781371
[TBL] [Abstract][Full Text] [Related]
17. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study.
Tsimikas S; Kiechl S; Willeit J; Mayr M; Miller ER; Kronenberg F; Xu Q; Bergmark C; Weger S; Oberhollenzer F; Witztum JL
J Am Coll Cardiol; 2006 Jun; 47(11):2219-28. PubMed ID: 16750687
[TBL] [Abstract][Full Text] [Related]
18. The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization.
Fefer P; Tsimikas S; Segev A; Sparkes J; Otsuka F; Kolodgie F; Virmani R; Juliano J; Charron T; Strauss BH
Cardiovasc Revasc Med; 2012; 13(1):11-9. PubMed ID: 22079685
[TBL] [Abstract][Full Text] [Related]
19. Increased inflammatory markers in children with familial hypercholesterolaemia.
Ueland T; Vissers MN; Wiegman A; Rodenburg J; Hutten B; Gullestad L; Ose L; Rifai N; Ridker PM; Kastelein JJ; Aukrust P; Semb AG
Eur J Clin Invest; 2006 Mar; 36(3):147-52. PubMed ID: 16506958
[TBL] [Abstract][Full Text] [Related]
20. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.
Kiechl S; Willeit J; Mayr M; Viehweider B; Oberhollenzer M; Kronenberg F; Wiedermann CJ; Oberthaler S; Xu Q; Witztum JL; Tsimikas S
Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1788-95. PubMed ID: 17541022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
